Table 3. Frequency of exams during follow-up.

	1° year	2° year	3° year	4° year	5° year	P value
	median times/year (range)
Low Risk Group
Blood chemistry test, No. 92	2 (0–4)	2 (0–4)	2 (0–3)	1 (0–2)	1 (0–2)	<0.0001
Tumor marker, No. 94	2 (0–4)	2 (0–4)	2 (0–3)	2 (0–3)	1 (0–2)	<0.0001
Chest radiograph, No. 80	1 (0–2)	1 (0–2)	1 (0–2)	0 (0–2)	0 (0–2)	<0.0001
Liver ultrasound, No. 87	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	0.45
Bone scan, No. 65	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0.48
Whole-body CT sca, No. 46	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0.32
Whole-body PET/CT scan, No. 46	0	0 (0–1)	0	0 (0–1)	0	0.41
High Risk Group
Blood chemistry tests, No. 92	3 (0–4)	3 (0–4)	2 (0–4)	2 (0–4)	2 (0–4)	<0.0001
Tumor markers, No. 94	3 (1–4)	3 (0–4)	2 (0–4)	2 (0–4)	2 (0–4)	<0.0001
Chest radiograph, No. 80	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	0.45
Liver ultrasound, No. 87	2 (0–2)	2 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	<0.0001
Bone scan, No. 65	1 (0–2)	1 (0–2)	1 (0–2)	0 (0–2)	0 (0–2)	<0.0001
Whole-body CT scan, No. 46	0.5 (0–2)	0 (0–2)	0 (0–1)	0 (0–1)	0 (0–1)	<0.0001
Whole-body PET/CT scan, No. 46	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0.57
Independently from Risk of Disease Progression
Blood chemistry tests, No. 19	2 (0–4)	2 (0–3)	2 (0–3)	1 (0–2)	1 (0–2)	<0.0001
Tumor markers, No. 20	3 (1–4)	3 (1–4)	2 (1–4)	2 (1–3)	1.5 (1–3)	<0.0001
Chest radiograph, No. 14	0.5 (0–2)	0 (0–2)	0 (0–1)	0 (0–1)	0 (0–1)	0.003
Liver ultrasound, No. 16	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–2)	0.45
Bone scans, No. 12	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0.48
Whole-body CT scan, No. 10	0	0	0	0	0	-
Whole-body PET/CT scan, No. 10	0	0	0	0	0	-

No.: number of responses.